Innovent Biologics (IVBXF) Short Interest Ratio & Short Volume $5.09 +0.45 (+9.71%) (As of 11/20/2024 ET) Add Compare Share Share Short Interest Stock AnalysisChartHeadlinesShort Interest Innovent Biologics Short Interest DataInnovent Biologics (IVBXF) has a short interest of 3.00 million shares. This marks a 11.21% increase in short interest from the previous month. The short interest ratio (days to cover) is 2,728.6, indicating that it would take 2,728.6 days of the average trading volume of 93,478 shares to cover all short positions.Current Short Interest3,001,500 sharesPrevious Short Interest2,699,000 sharesChange Vs. Previous Month+11.21%Dollar Volume Sold Short$13.71 millionShort Interest Ratio2,728.6 Days to CoverLast Record DateOctober 31, 2024Today's Trading Volume14,300 sharesAverage Trading Volume93,478 sharesToday's Volume Vs. Average15% Short Selling Innovent Biologics? Sign up to receive the latest short interest report for Innovent Biologics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartIVBXF Short Interest Over TimeIVBXF Days to Cover Over TimeIVBXF Percentage of Float Shorted Over Time Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Innovent Biologics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/20243,001,500 shares $13.71 million +11.2%N/A2728.6 $4.57 10/15/20242,699,000 shares $15.92 million +1.6%N/A39.6 $5.90 9/30/20242,656,700 shares $16.29 million -0.7%N/A1021.8 $6.13 9/15/20242,674,100 shares $14.92 million -2.7%N/A40.2 $5.58 8/31/20242,747,600 shares $14.42 million -9.1%N/A1248.9 $5.25 8/15/20243,022,000 shares $16.33 million -0.2%N/A46.5 $5.40 Get the Latest News and Ratings for IVBXF and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Innovent Biologics and its competitors with MarketBeat's FREE daily newsletter. 7/31/20243,026,700 shares $14.57 million +1.4%N/A738.2 $4.82 7/15/20242,986,300 shares $14.95 million +0.8%N/A3732.9 $5.01 6/30/20242,961,500 shares $13.94 million -0.3%N/A224.4 $4.71 6/15/20242,971,000 shares $14.65 million +13.3%N/A380.9 $4.93 5/31/20242,622,200 shares $11.77 million -20.3%N/A639.6 $4.49 5/15/20243,291,500 shares $16.72 million -3.4%N/A1097.2 $5.08 4/30/20243,408,800 shares $16.77 million -1.7%N/A2272.5 $4.92 4/15/20243,466,300 shares $15.94 million +8.6%N/A990.4 $4.60 3/31/20243,191,000 shares $15.60 million +1.6%N/A2454.6 $4.89 3/15/20243,140,300 shares $17.21 million -1.7%N/A107.5 $5.48 2/29/20243,193,000 shares $17.37 million +0.1%N/A570.2 $5.44 2/15/20243,189,100 shares $14.80 million +4.4%N/A1328.8 $4.64 1/15/20241,425,700 shares $7.68 million -11.1%N/A1.9 $5.39 12/31/20231,602,800 shares $7.89 million -16.1%N/A7.3 $4.92 12/15/20231,909,700 shares $10.16 million +28.7%N/A187.2 $5.32 11/30/20231,484,300 shares $8.62 million -10.1%N/A1349.4 $5.81 11/15/20231,651,800 shares $9.76 million -36.2%N/A611.8 $5.91 10/31/20232,590,000 shares $15.24 million -23.3%N/A893.1 $5.89 10/15/20233,377,500 shares $16.89 million +1.0%N/A1250.9 $5.00 9/30/20233,343,500 shares $16.72 million -35.2%N/A33435 $5.00 9/15/20235,158,800 shares $22.63 million +1.6%N/A17196 $4.39 8/31/20235,077,800 shares $18.03 million -9.5%N/A990 $3.55 8/15/20235,608,800 shares $19.91 million +0.3%N/A277.7 $3.55 7/31/20235,592,800 shares $21.87 million -2.3%N/A55928 $3.91 7/15/20235,725,300 shares $22.39 million -3.4%N/A1908.4 $3.91 6/30/20235,926,700 shares $23.65 million +3.1%N/A2694 $3.99 6/15/20235,748,000 shares $27.48 million -7.3%N/A11496 $4.78 5/31/20236,202,800 shares $29.40 million -0.6%N/A8861.1 $4.74 5/15/20236,241,300 shares $31.46 million +0.6%N/A12482.6 $5.04 4/30/20236,201,800 shares $29.83 million -3.7%N/A7752.3 $4.81 4/15/20236,436,800 shares $30.38 million -1.0%N/A1129.3 $4.72 3/31/20236,498,300 shares $31.00 million -5.0%N/A3420.2 $4.77 3/15/20236,837,300 shares $32.61 million +10.4%N/A2629.7 $4.77 2/28/20236,192,300 shares $29.54 million -2.9%N/A6880.3 $4.77JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. 2/15/20236,375,300 shares $34.21 million +5.4%N/A3035.9 $5.37 1/31/20236,048,300 shares $32.96 million -0.2%N/A2160.1 $5.45 1/15/20236,061,300 shares $32.55 million -0.8%N/A993.7 $5.37 12/30/20226,111,900 shares $26.19 million +0.3%N/A442.9 $4.29 12/15/20226,091,900 shares $25.83 million -3.4%N/A2343 $4.24 11/30/20226,306,100 shares $24.91 million -10.4%N/A750.7 $3.95 11/15/20227,034,100 shares $30.95 million -1.8%N/A1153.1 $4.40 10/31/20227,160,600 shares $25.42 million +11.5%N/A1256.2 $3.55 10/15/20226,420,100 shares $17.39 million -0.6%N/A12840.2 $2.71 9/30/20226,456,100 shares $24.06 million +7.3%N/A64561 $3.73 9/15/20226,014,600 shares $22.41 million -17.2%N/A20048.7 $3.73 8/31/20227,264,400 shares $29.42 million -4.1%N/A10377.7 $4.05 8/15/20227,577,900 shares $35.39 million +19.3%N/A1353.2 $4.67 7/31/20226,351,000 shares $27.06 million +28.7%N/A1814.6 $4.26 7/15/20224,934,200 shares $22.57 million +16.6%N/A1762.2 $4.58 6/30/20224,231,400 shares $17.14 million +6.5%N/A4701.6 $4.05 6/15/20223,971,900 shares $13.50 million +22.1%N/A39719 $3.40 5/31/20223,254,400 shares $9.44 million +4.1%N/A1549.7 $2.90 5/15/20223,126,900 shares $7.19 million +39.0%N/A3126.9 $2.30 4/30/20222,249,900 shares $6.95 million +14.4%N/A4499.8 $3.09 4/15/20221,966,500 shares $6.45 million -15.7%N/A357.5 $3.28 3/31/20222,332,500 shares $8.00 million -36.7%N/A5831.3 $3.43 3/15/20223,686,200 shares $11.01 million +21.2%N/A1228.7 $2.99 2/28/20223,041,700 shares $12.52 million +3.7%N/A822.1 $4.12 2/15/20222,933,300 shares $11.94 million +0.1%N/A329.6 $4.07 1/31/20222,929,200 shares $11.61 million +89.9%N/A4184.6 $3.97 1/15/20221,542,800 shares $7.93 million -12.1%N/A177.3 $5.14 12/31/20211,754,300 shares $10.79 million -26.0%N/A302.5 $6.15 12/15/20212,372,000 shares $17.20 million -3.0%N/A62.6 $7.25 11/30/20212,445,300 shares $22.84 million +4.4%N/A1438.4 $9.34 11/15/20212,341,800 shares $23.35 million -9.9%N/A669.1 $9.97 10/29/20212,598,800 shares $23.86 million -4.0%N/A3712.6 $9.18 10/15/20212,707,000 shares $26.93 million +30.8%N/A86.2 $9.95 9/30/20212,070,300 shares $20.70 million +24.0%N/A178.5 $10.00 9/15/20211,669,000 shares $13.35 million -22.5%N/A3338 $8.00 8/31/20212,153,700 shares $22.61 million -10.3%N/A1794.8 $10.50 8/13/20212,402,200 shares $25.22 million +7.0%N/A12011 $10.50 7/30/20212,244,200 shares $26.71 million -0.5%N/A202.2 $11.90 7/15/20212,255,200 shares $26.84 million -1.4%N/A22552 $11.90 6/30/20212,287,200 shares $27.22 million +4.6%N/A3812 $11.90 6/15/20212,186,200 shares $24.29 million -14.2%N/A809.7 $11.11 5/28/20212,548,500 shares $30.58 million -9.9%N/A1415.8 $12.00 5/14/20212,828,000 shares $36.76 million +5.6%N/A140.7 $13.00 4/30/20212,678,000 shares $34.81 million -4.7%N/A26780 $13.00 4/15/20212,808,800 shares $36.51 million -4.2%N/A1652.2 $13.00 3/31/20212,931,300 shares $26.82 million -4.5%N/A945.6 $9.15 3/15/20213,069,800 shares $30.70 million -0.9%N/A7674.5 $10.00 2/26/20213,096,800 shares $36.51 million +1.2%N/A3096.8 $11.79 2/12/20213,060,400 shares $40.09 million -1.0%N/A624.6 $13.10 1/29/20213,092,400 shares $40.20 million -5.2%N/A524.1 $13.00JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. 1/15/20213,952,800 shares $41.50 million +13.2%N/A79.9 $10.50 12/31/20203,410,300 shares $32.94 million -13.7%N/A79.1 $9.66 12/15/20203,952,800 shares $29.25 million +13.2%N/A79.9 $7.40 11/30/20203,491,500 shares $24.27 million +30.4%N/A130.3 $6.95 11/15/20202,677,300 shares $18.74 million +16.2%N/A134.5 $7.00 10/30/20202,303,300 shares $18.43 million +3.7%N/A205.7 $8.00 10/15/20202,221,300 shares $16.55 million +5.6%N/A2468.1 $7.45 9/30/20202,102,800 shares $15.67 million +5.0%N/A412.3 $7.45 9/15/20202,003,000 shares $13.74 million +4.5%N/A83.8 $6.86 8/31/20201,916,000 shares $12.93 million +23.0%N/A57.9 $6.75 8/14/20201,558,300 shares $10.28 million +10.9%N/A38.7 $6.60 7/31/20201,404,900 shares $8.43 million +8.9%N/A265.1 $6.00 7/15/20201,289,900 shares $9.30 million +3.0%N/A30.4 $7.21 6/30/20201,252,600 shares $0.00 +10.9%N/A56.7 $0.00 6/15/20201,129,600 shares $0.00 +19.3%N/A225.9 $0.00 5/29/2020947,000 shares $5.51 million +10.4%N/A44.9 $5.82 5/15/2020857,900 shares $4.55 million +9.9%N/A451.5 $5.30 4/30/2020780,700 shares $0.00 -5.9%N/A110 $0.00 4/15/2020830,000 shares $0.00 -4.7%N/A38.2 $0.00 3/31/2020870,500 shares $4.35 million +10.8%N/A62.2 $5.00 3/13/2020785,500 shares $3.30 million -34.2%N/A374 $4.20 2/28/20201,194,500 shares $0.00 -6.2%N/A29.9 $0.00 2/14/20201,274,000 shares $5.41 million -27.2%N/A102.7 $4.25 1/31/20201,749,500 shares $0.00 -4.0%N/A115.9 $0.00 1/15/20201,823,000 shares $7.22 million -17.2%N/A48.6 $3.96 12/31/20192,202,000 shares $9.38 million +4.2%N/A38.9 $4.26 IVBXF Short Interest - Frequently Asked Questions What is Innovent Biologics' current short interest? Short interest is the volume of Innovent Biologics shares that have been sold short but have not yet been closed out or covered. As of October 31st, traders have sold 3,001,500 shares of IVBXF short. Learn More on Innovent Biologics' current short interest. What is a good short interest ratio for Innovent Biologics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IVBXF shares currently have a short interest ratio of 2,729.0. Learn More on Innovent Biologics's short interest ratio. Is Innovent Biologics' short interest increasing or decreasing? Innovent Biologics saw a increase in short interest in October. As of October 31st, there was short interest totaling 3,001,500 shares, an increase of 11.2% from the previous total of 2,699,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Innovent Biologics stock? Short selling IVBXF is an investing strategy that aims to generate trading profit from Innovent Biologics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Innovent Biologics? A short squeeze for Innovent Biologics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of IVBXF, which in turn drives the price of the stock up even further. How often is Innovent Biologics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IVBXF, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies 180 Life Sciences Short Interest Data 3SBio Short Interest Data Algernon Pharmaceuticals Short Interest Data Alpha Tau Medical Short Interest Data Anew Medical Short Interest Data Apollomics Short Interest Data Ascentage Pharma Group International Short Interest Data Ascletis Pharma Short Interest Data Avacta Group Short Interest Data Awakn Life Sciences Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:IVBXF) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innovent Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innovent Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
